ALIPAY+
13.1.2023 10:33:43 CET | Business Wire | Press release
Alipay+, a provider of global cross-border digital payment and marketing solutions announced today that, through Alipay+, Macao merchants are offering lucrative incentives inside AlipayHK – one of the most popular e-wallets in Hong Kong – to attract travelers and boost local consumption as inter-city travels are expected to soon recovered to pre-pandemic levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230113005107/en/
From January 20, users of AlipayHK will be able to find featured Macao shops and their special offers for tourists such as digital coupons inside the app’s Alipay+ Rewards section. (Photo: Business Wire)
From January 20, users of AlipayHK will be able to find featured Macao shops and their special offers for tourists such as digital coupons inside the app’s Alipay+ Rewards section – a joint effort of several parties including Macao’s Economic and Technological Development Bureau, five local chambers of commerce, Macau Pass, Ant Group and over a hundred small and medium-sized merchants in Macao.
The latest campaign inside AlipayHK’s Alipay+ Rewards section was established to boost local consumption as more and more tourists return to the city. AlipayHK, which owns most active users in Hong Kong, has been accepted at nearly 90% merchants in Macao.
“Powered by Alipay+, this online campaign on AlipayHK, which has 3.3 million active users, will help promote local Macao merchants and increase their exposures, as well as position Macao as an attractive tourist destination for travelers from Hong Kong in the short- to longer-term,” said Ng Wah Wai, Director of the Industry and Commerce Association of Macau. He added that the campaign is also expected to connect Macao merchants with more tourists from other overseas markets through Alipay+ in the future.
“With the joint efforts from all parties, we hope this campaign on AlipayHK could further explore the potential of Macao’s featured merchants via online promotion, enhance the attractiveness of Macao’s tourism consumption, encourage the second and third-time visits of tourists to Macao, and jointly create new momentum for Macao’s overall economic growth,” said Ng.
On January 8, China announced first steps to optimize regulations on travel between the mainland and Hong Kong, lifting quarantine requirements that were in place for almost three years. A surge in number of travelers between the two cities is expected in response to the relaxation of travel restrictions.
Venetia Lee, General Manager of Ant Group Greater China International Business, said: “We are pleased to work with the Macao government and five local chambers of commerce to attract more Hong Kong tourists to Macao and stimulate local tourism consumption, in recognition of AlipayHK as a valuable partner.”
“AlipayHK is dedicated to playing a greater role in the realization of connectivity in the Great Bay Area through Alipay+ payment and marketing solutions, and we will continue to work with different ecological partners in the future to provide more convenient and valuable services to our users,” she added.
Alipay+’s Expanding Global Footprint
Developed by Ant Group, Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by merchants through Alipay+.
Alipay+ Rewards is a new digital marketing platform developed by Alipay+ and partner e-wallets to help global brands better engage with consumers worldwide by offering incentives and exclusive services.
Currently, Alipay+ has over 15 mobile payment partners globally, including AlipayHK, that have covered more than 1 billion digital-savvy consumers. South Korea’s Kakao Pay, another e-wallet partners of Alipay+, has also been accepted at local merchants in Macao.
Globally, over the past year, Alipay+’s merchant coverage has more than doubled since last year to over 2.5 million, which includes regional and global digital entertainment providers, lifestyle services, e-commerce platforms and a wide range of brick-and-mortar businesses that cover major airports, shopping centers, duty free shops, convenience stores, cafes, restaurants and tourism facilities.
Businesses across Japan, South Korea, Singapore, Malaysia and other Southeast Asian markets are embracing Alipay+ to connect with global digital payment methods through one-time integration, and better engage with over 1 billion consumers.
Alipay+’s merchant coverage includes over 1,000 online platforms, more than 10 major airports, over 90,000 convenience stores, over 360,000 restaurants, nearly 200,000 taxis and major hotel brands, department stores, duty-free shops and tourist facilities in Asia and Europe.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
